respiratory
Cystic fibrosis

New CF drug gets TGA approval


The TGA has approved a new cystic fibrosis treatment tezacaftor/ivacaftor (Symdeko) for patients aged 12 and older. Manufacturer Vertex announced  on 12 March that its drug (tezacaftor 100 mg/ivacaftor 150 mg tablet and ivacaftor 150 mg tablets) had been approved by the TGA for patients with F508del and residual function mutations in the CF transmembrane ...

Already a member?

Enter your email to keep reading.


OR